All In Biotech

Free tool

FAERS Monitor: Celontin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 010596 or its brand name (Celontin, Methsuximide). Reports on generic versions are filed under their own applications.

Reports

182

Serious

107

59% of reports

Hospitalization

39

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective25
  • seizure21
  • convulsion14
  • dizziness13
  • somnolence13
  • feeling abnormal11
  • generalised tonic-clonic seizure11
  • off label use11
  • fall9
  • asthenia8
  • drug interaction8
  • fatigue8
  • therapeutic product effect incomplete7
  • condition aggravated6
  • toxicity to various agents6

Reports by year received

View as table
YearReports
20046
20053
20062
20072
20093
20107
20112
20129
20136
20146
201513
201610
20177
201821
201915
202015
202114
202214
20236
20249
20256
20266

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,977 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
generalised tonic-clonic seizureSignal1176.943.3750
convulsionSignal1428.317.1343
seizureSignal2121.014.1383
therapeutic product effect incompleteSignal711.45.556
somnolenceSignal137.54.467
drug interactionSignal85.83.028
feeling abnormalSignal115.33.035
toxicity to various agentsSignal64.11.911
fallSignal93.11.711
dizzinessSignal133.01.816
astheniaSignal82.51.26
condition aggravated62.31.03
drug ineffectiveSignal252.21.516
off label use111.50.81
fatigue81.20.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.